加拿大皇家银行将Verve Therapeutics的目标价从25美元下调至20美元，维持“跑赢大盘”评级。 RBC lowers Verve Therapeutics' price target to $20 from $25, retains "outperform" rating.

加拿大皇家银行 (RBC) 将Verve Therapeutics的 (NASDAQ:VERV) 目标价格从25美元降至20美元,保持"超越"评级. Royal Bank of Canada (RBC) cut Verve Therapeutics' (NASDAQ:VERV) price target from $25.00 to $20.00, retaining an "outperform" rating. HC Wainwright还重申了“买”评级,设定了15美元的目标价格。 HC Wainwright also reiterated a "buy" rating and set a $15.00 target price. 尽管净差额和公平回报为负,但临床阶段遗传药物公司Verve治疗公司正在研制心血管疾病的基因编辑治疗。 Despite negative net margin and return on equity, Verve Therapeutics, a clinical-stage genetic medicines firm, is developing gene editing treatments for cardiovascular diseases.